ARTICLE | Company News
Absynth Biologics, MorphoSys deal
September 6, 2010 7:00 AM UTC
The companies will discover and develop antibodies against Absynth's targets associated with Staphylococcus aureus infections, including methicillin-resistant S. aureus (MRSA). MorphoSys will generate...